Literature DB >> 3141117

Elimination of antibiotic-resistant plasmids by quinolone antibiotics.

K P Fu1, M E Grace, C L Hsiao, P P Hung.   

Abstract

Of 7 plasmids we tested, the plasmid pORF2 was eliminated in vitro with the most efficiency by treatment with subinhibitory concentrations of novobiocin, coumermycin and 10 quinolones. It showed a cure rate of 43% by enoxacin; 12% by novobiocin, pefloxacin, ciprofloxacin and CI-934; 7% by coumermycin and ofloxacin; 9% by amifloxacin; and 4% by AM-833. On the other hand, pSC194, pBR322 and pMH612 were poorly cured in vitro by quinolones, except pSC194 which was cured 33% by enoxacin. R1, pP1603, and pUB110 were unaffected by the treatment. Mice were challenged intraperitoneally with a 2XLD50 of Escherichia coli carrying the ORF2 plasmid and were treated per os with 1 X or 1/2 X ED50 of either enoxacin or CI-934. The frequency of loss of ampicillin resistance determined 3 h after treatment shows curing effects of 92% for CI-934, 89% for enoxacin and 20% for untreated control.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3141117     DOI: 10.1159/000238601

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  9 in total

1.  Subinhibitory antimicrobial concentrations: A review of in vitro and in vivo data.

Authors:  G G Zhanel; D J Hoban; G K Harding
Journal:  Can J Infect Dis       Date:  1992-07

Review 2.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

3.  Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus.

Authors:  J Fung-Tomc; B Kolek; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

4.  Activity of quinolones in the Ames Salmonella TA102 mutagenicity test and other bacterial genotoxicity assays.

Authors:  S W Mamber; B Kolek; K W Brookshire; D P Bonner; J Fung-Tomc
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

5.  Energy-dependent mitochondrial mutagenicity of antibacterial ofloxacin and its recombinogenic activity in yeast.

Authors:  M Obernauerová; J Subík
Journal:  Curr Genet       Date:  1994-09       Impact factor: 3.886

Review 6.  Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.

Authors:  J A Balfour; P A Todd; D H Peters
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

Review 7.  Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy.

Authors:  R Davis; H M Bryson
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

Review 8.  Targeting Plasmids to Limit Acquisition and Transmission of Antimicrobial Resistance.

Authors:  Corneliu Ovidiu Vrancianu; Laura Ioana Popa; Coralia Bleotu; Mariana Carmen Chifiriuc
Journal:  Front Microbiol       Date:  2020-05-06       Impact factor: 5.640

Review 9.  Strategies to combat antimicrobial resistance: anti-plasmid and plasmid curing.

Authors:  Michelle M C Buckner; Maria Laura Ciusa; Laura J V Piddock
Journal:  FEMS Microbiol Rev       Date:  2018-11-01       Impact factor: 16.408

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.